Piotr Sawrycki

2.1k total citations
14 papers, 151 citations indexed

About

Piotr Sawrycki is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Surgery. According to data from OpenAlex, Piotr Sawrycki has authored 14 papers receiving a total of 151 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Pulmonary and Respiratory Medicine, 10 papers in Oncology and 7 papers in Surgery. Recurrent topics in Piotr Sawrycki's work include Renal cell carcinoma treatment (8 papers), Bladder and Urothelial Cancer Treatments (7 papers) and Cancer Immunotherapy and Biomarkers (7 papers). Piotr Sawrycki is often cited by papers focused on Renal cell carcinoma treatment (8 papers), Bladder and Urothelial Cancer Treatments (7 papers) and Cancer Immunotherapy and Biomarkers (7 papers). Piotr Sawrycki collaborates with scholars based in Poland, United States and France. Piotr Sawrycki's co-authors include Bogusław Buszewski, A. Ulanowska, Stefan N. Symeonides, Marine Gross‐Goupil, Jaroslav Hájek, Jae‐Lyun Lee, Se Hoon Park, Toni K. Choueiri, Naveed Sarwar and Piotr Tomczak and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Annals of Oncology.

In The Last Decade

Piotr Sawrycki

14 papers receiving 148 citations

Peers

Countries citing papers authored by Piotr Sawrycki

Since Specialization

Citations

This map shows the geographic impact of Piotr Sawrycki's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Piotr Sawrycki with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Piotr Sawrycki more than expected).

Fields of papers citing papers by Piotr Sawrycki

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Piotr Sawrycki. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Piotr Sawrycki. The network helps show where Piotr Sawrycki may publish in the future.

Co-authorship network of co-authors of Piotr Sawrycki

This figure shows the co-authorship network connecting the top 25 collaborators of Piotr Sawrycki. A scholar is included among the top collaborators of Piotr Sawrycki based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Piotr Sawrycki. Piotr Sawrycki is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

14 of 14 papers shown

#	Work	Indexed citations
1	Five-year follow-up results from the phase 3 KEYNOTE-564 study of adjuvant pembrolizumab (pembro) for the treatment of clear cell renal cell carcinoma (ccRCC). 2025 ·Journal of Clinical Oncology ·Naomi B. Haas, Thomas Powles, Piotr Tomczak, Se Hoon Park, Balaji Venugopal, Stefan N. Symeonides, Tom Ferguson, Warren Chang, Jae‐Lyun Lee, Piotr Sawrycki, Naveed Sarwar, Howard Gurney, Marine Gross‐Goupil, John M. Burke, (unknown), (unknown), Joseph E. Burgents, Rodolfo F. Perini, Toni K. Choueiri	1
2	Overall survival results from the phase 3 KEYNOTE-564 study of adjuvant pembrolizumab versus placebo for the treatment of clear cell renal cell carcinoma (ccRCC). 2024 ·Journal of Clinical Oncology ·Toni K. Choueiri, Piotr Tomczak, Se Hoon Park, Balaji Venugopal, Thomas Ferguson, Stefan N. Symeonides, Jaroslav Hájek, Yen‐Hwa Chang, Jae‐Lyun Lee, Naveed Sarwar, Howard Gurney, Marine Gross‐Goupil, Mauricio Mahave, Naomi B. Haas, Piotr Sawrycki, Tian Zhang, (unknown), Aymen Elfiky, Joseph E. Burgents, Thomas Powles	22
3	Abstract CT202: Xevinapant plus avelumab in patients (pts) with advanced or metastatic non-small cell lung cancer (NSCLC): Phase 1b dose-expansion results and exploratory biomarker analyses 2023 ·Cancer Research ·Quincy S. Chu, Tudor–Eliade Ciuleanu, Rodryg Ramlau, Daniel J. Renouf, Rosalyn A. Juergens, Ewa Kalinka‐Warzocha, Piotr Sawrycki, Jonathan L. Bramson, Brad H. Nelson, (unknown), Daniela A. Sahlender, (unknown), Elisabeth Rouits, (unknown), Franck Brichory, (unknown), M Schenker, Glenwood Goss	1
4	Adjuvant pembrolizumab (pembro) for renal cell carcinoma (RCC) across UCLA Integrated Staging System (UISS) risk groups and disease stage: Subgroup analyses from the KEYNOTE-564 study. 2023 ·Journal of Clinical Oncology ·Toni K. Choueiri, Piotr Tomczak, Se Hoon Park, Balaji Venugopal, Tom Ferguson, Stefan N. Symeonides, Jaroslav Hájek, Yen-Hwa Chang, Jae‐Lyun Lee, Naveed Sarwar, Antoine Thiery-Vuillemin, Marine Gross‐Goupil, Mauricio Mahave, Naomi B. Haas, Piotr Sawrycki, Tian Zhang, Lei Xu, (unknown), Christian Poehlein, Thomas Powles	3
5	Pembrolizumab as post nephrectomy adjuvant therapy for patients with renal cell carcinoma: Results from 30-month follow-up of KEYNOTE-564. 2022 ·Journal of Clinical Oncology ·Toni K. Choueiri, Piotr Tomczak, Se Hoon Park, Balaji Venugopal, Tom Ferguson, Stefan N. Symeonides, Jaroslav Hájek, Yen‐Hwa Chang, Jae‐Lyun Lee, Naveed Sarwar, Antoine Thiery-Vuillemin, Marine Gross‐Goupil, Mauricio Mahave, Naomi B. Haas, Piotr Sawrycki, Lei Xu, Kentaro Imai, (unknown), David I. Quinn, Thomas Powles	20
6	Adjuvant pembrolizumab for postnephrectomy renal cell carcinoma (RCC): Expanded efficacy analyses from KEYNOTE-564. 2022 ·Journal of Clinical Oncology ·Toni K. Choueiri, Piotr Tomczak, Se Hoon Park, Balaji Venugopal, Tom Ferguson, Stefan N. Symeonides, Jaroslav Hájek, Yen‐Hwa Chang, Jae‐Lyun Lee, Naveed Sarwar, Antoine Thiery-Vuillemin, Marine Gross‐Goupil, Mauricio Mahave, Naomi B. Haas, Piotr Sawrycki, Howard Gurney, Lei Xu, (unknown), (unknown), Thomas Powles	4
7	Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for patients with renal cell carcinoma: Randomized, double-blind, phase III KEYNOTE-564 study. 2021 ·Journal of Clinical Oncology ·Toni K. Choueiri, Piotr Tomczak, Se Hoon Park, Balaji Venugopal, Tom Ferguson, Yen‐Hwa Chang, Jaroslav Hájek, Stefan N. Symeonides, Jae‐Lyun Lee, Naveed Sarwar, Antoine Thiery-Vuillemin, Marine Gross‐Goupil, Mauricio Mahave, Naomi B. Haas, Piotr Sawrycki, Éric Zhang, (unknown), Kentaro Imai, David I. Quinn, Thomas Powles	26
8	653O Pembrolizumab (pembro) vs placebo as adjuvant therapy for patients (pts) with renal cell carcinoma (RCC): Patient-reported outcomes (PRO) in KEYNOTE-564 2021 ·Annals of Oncology ·Toni K. Choueiri, Piotr Tomczak, S.H. Park, B. Venugopal, (unknown), J Hájek, Thomas Ferguson, (unknown), J.L. Lee, Naomi B. Haas, Piotr Sawrycki, Naveed Sarwar, Marine Gross‐Goupil, Antoine Thiery-Vuillemin, Mauricio Mahave, (unknown), (unknown), (unknown), David I. Quinn, T.B. Powles	1
9	Aurora A Functional Single Nucleotide Polymorphism (SNP) Correlates With Clinical Outcome in Patients With Advanced Solid Tumors Treated With Alisertib, an Investigational Aurora A Kinase Inhibitor 2020 ·UNC Libraries ·Gerald S. Falchook, Ursula A. Matulonis, (unknown), Jeffrey Ecsedy, (unknown), Brittany Bahamón, Robert L. Coleman, (unknown), Kimberly Perez, Antoine Adenis, Bohuslav Melichar, Feng Gao, Hadi Danaee, Elizabeth Claire Dees, Kian Behbakht, Piotr Sawrycki, Dirk Huebner, Hyunjin Shin, Angela DeMichele	1
10	Abstract CT162: Pembrolizumab monotherapy for the adjuvant treatment of renal cell carcinoma post-nephrectomy: Randomized, double-blind, Phase III KEYNOTE-564 study 2019 ·Cancer Research ·Toni K. Choueiri, David I. Quinn, Tian Zhang, Howard Gurney, Gurjyot K. Doshi, Patrick Cobb, Francis Parnis, Jae‐Lyun Lee, Se Hoon Park, Andrey Semenov, Antoine Thiery-Vuillemin, Piotr Sawrycki, Piotr Tomczak, B. Yа. Alekseev, А. А. Измайлов, (unknown), Shuyan Wan, Christian Poehlein, (unknown), Thomas Powles	1
11	Relationship Between CYP1B1 Polymorphisms (c.142C > G, c.355G > T, c.1294C > G) and Lung Cancer Risk in Polish Smokers 2018 ·Future Oncology ·Piotr Sawrycki, Krzysztof Domagalski, (unknown), (unknown), Joanna Jarkiewicz‐Tretyn, Andrzej Tretyn	3
12	Aurora A Functional Single Nucleotide Polymorphism (SNP) Correlates With Clinical Outcome in Patients With Advanced Solid Tumors Treated With Alisertib, an Investigational Aurora A Kinase Inhibitor 2017 ·EBioMedicine ·Huifeng Niu, Hyunjin Shin, Feng Gao, (unknown), Brittany Bahamón, Hadi Danaee, Bohuslav Melichar, (unknown), Robert L. Coleman, Gerald S. Falchook, Antoine Adenis, Kian Behbakht, Angela DeMichele, Elizabeth Claire Dees, Kimberly Perez, Ursula A. Matulonis, Piotr Sawrycki, Dirk Huebner, Jeffrey Ecsedy	12
13	Randomised phase II study of axitinib or bevacizumab combined with paclitaxel/carboplatin as first-line therapy for patients with advanced non-small-cell lung cancer 2013 ·Annals of Oncology ·Chris Twelves, Ewa Chmielowska, Libor Havel, Sanjay Popat, Anna Świeboda-Sadlej, Piotr Sawrycki, Paul Bycott, Antonella Ingrosso, S. Kim, James A. Williams, C. Chen, Anthony J. Olszanski, Pietro De Besi, Joan H. Schiller	30
14	Chemotherapy control by breath profile with application of SPME‐GC/MS method 2012 ·Journal of Separation Science ·A. Ulanowska, (unknown), Piotr Sawrycki, Bogusław Buszewski	26

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact